BiondVax Agrees to Develop Nanosized COVID-19 Antibody therapy

Dec 22, 2021 By MarketDepth

Biotechnology Business Headlines Healthcare Investing What's Hot

Covid19 Vaccine

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) has reported signature on a definitive agreement with the Max Planck Society, parent organization of Max Planck Institute of Biophysical Chemistry and the University Medical Center Gottingen, to enter into a partnership for the development and commercialization of innovative COVID-19 nanosized antibodies.  Mr. Amir Reichman, BiondVax’s CEO, commented, “As Omicron’s recent and rapid emergence makes clear, improved therapeutics are needed to bring COVID-19 under control. The innovative COVID-19 NanoAb candidates offer the potential for a superior therapeutic platform. Overall, the NanoAb platform is an incredible opportunity for BiondVax. It will serve as a basis for an exciting new pipeline of commercially attractive products to address unmet therapeutic needs of diseases such as psoriasis, psoriatic arthritis, asthma, and macular degeneration. The technology is a great fit to our manufacturing site in Jerusalem and our experience and expertise in biological drug development. I wish to thank Professors Görlich and Dobbelstein for their enthusiasm for this project, and Max Planck Innovation’s technology transfer team including Dr. Dieter Link for their assistance in developing this innovative collaboration. BiondVax is in the process of a transformative turnaround, and I am highly confident that these NanoAb therapies present compelling commercial potential and will address important healthcare needs.”

“We believe that the innovative platform developed at the Max Planck Institute for Biophysical Chemistry and the University Medical Center of Göttingen has great potential to provide patients with superior therapies. We are particularly pleased to team with BiondVax to use their drug development and manufacturing capabilities and expertise to advance the COVID-19 nanosized antibodies through additional development towards marketing approvals.”

Professor Dirk Görlich, Director at the Max Planck Institute for Biophysical Chemistry